bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P4-17-06: Treatment strategies in male breast cancer: Results of a prospective multicenter study
Authors: Eggemann Holm , Brucker Cosima , Schirrmeister Susen , Ringsdorf Uta , Augustin Doris , Schrauder Michael , Thill Marc , Flock Felix , Kraudelt Susanne , Gad Gabriele , Kleine-Tebbe Anke , Reinisch Mattea , Dan Costa Serban- , Ignatov Atanas 
Published: March 2020

Abstract
Background. In this prospective analysis, we aimed to characterize the treatment opinions on male breast cancer (MBC). Patients and methods. In this prospective cohort study we included patients treated between May2009 and June 2018 for MBC. Results. The median follow-up was 30 months (range 2-84 months) and the median age at diagnosis was 69 years (range 27-96 years). Radical mastectomy was performed in 354 (96.2%) cases. Most (n=194, 52.9%) patients underwent sentinel-node biopsy (SNB). However, the vast majority of patients with clinical and sonographic suspicious axillary lymph nodes (n=72, 81.8%) underwent ALND. Adjuvant radiation of chest wall post mastectomy or of the breast post breast conserving surgery was performed in 193 (51.9%) patients. Systemic therapy was administered to 155 (41.0%) patients, and was administered predominantly in the adjuvant setting. Most common was anthracycline-taxane-based therapy. Of patients with HER2 (n=43) overexpressing tumors, 29 (67.4%) received trastuzumab. Adjuvant endocrine therapy was administered to 92.3% of patients, predominantly tamoxifen. Important decision criteria for adjuvant radiation and chemotherapy were advanced stage of disease, lymph node metastases, undifferentiated tumors, lymph- and blood vessel invasion. During the follow up period 609 cycles of chemotherapy were administered (median 6 cycles per person). Haematological and non-haematological toxic effects were observed in 68 (16.4%) and 57 (53.3%) patients, respectively. Grade 3 and 4 haematological events were rare. The most common was neutropenia in 17 (15.8%) and febrile neutropenia in 10 (9.3%) cases. Nausea and vomiting were the most commonly observed grade 3 and 4 non-haematological adverse events observed in 7 (4.6%) cases. Endocrine therapy was discontinued in 53 (16.2%) patients and chemotherapy in 25 (16.1%) cases. Conclusions. In this large prospective study, we found that MBC is treated according to current guidelines and treatment seems to be not inferior in comparison with that treatment of FBC.
Citation Format: Holm Eggemann, Cosima Brucker, Susen Schirrmeister, Uta Ringsdorf, Doris Augustin, Michael Schrauder, Marc Thill, Felix Flock, Susanne Kraudelt, Gabriele Gad, Anke Kleine-Tebbe, Mattea Reinisch, Serban- Dan Costa, Atanas Ignatov. Treatment strategies in male breast cancer: Results of a prospective multicenter study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-17-06.
Abstract P5-01-02: Identification and validation of a serum microRNA panel for detection of early-stage breast cancer
Authors: Zhou Lihan , Zou Ruiyang , Loke Sau Yeen , Hartman Mikael , Goo Patrick C.K , Lee-Lim Ann S.G. , Too Heng-Phon 
Published: March 2020

Abstract
Background: Survival outcomes of breast cancer patients can be significantly improved by early detection and treatment. Implementation of mammogram-based screening has significantly improved early detection of breast cancer in the west. However, the use of screening mammography is less prevalent in Asia partly due to social and cultural reasons. The aim of this study was to determine if a serum microRNA (miRNA) panel could be used as blood-based biomarkers to assist in the early detection of breast cancer.
Methods: We carried out a multi-center, multi-ethnic study to identify and validate miRNA biomarkers for the early detection of breast cancer. A total of 1042 subjects including 540 breast cancer cases (predominantly stage 1 and 2 cases) and 502 matched controls from 6 independent sources were included in this study. Among these, there were 750 American and European subjects recruited by biobanks and 292 Singaporean Asian Subjects recruited at the National Cancer Centre Singapore and the National University Hospital. The study was conducted in 3 phases in which sera of 289 European Caucasian serum samples (Discovery Cohort) were first interrogated to identify differentially expressed miRNAs between early-stage breast cancer cases and matched controls among 520 circulating miRNA candidates by quantitative RT-PCR using MiRXES assays. The remaining 753 subjects from 5 independent sources were assigned into two groups for biomarker optimization/algorithm development (Optimization Cohort, n=374) and validation (Validation Cohort, n=379).
Results: Among the 520 circulating miRNAs measured, 241 were quantified in absolute copy numbers for 289 subjects in the Discovery Cohort. Thirty-three candidate miRNAs were identified. These miRNAs consistently showed differential expression between cancer and control subjects in the Optimization Cohort. A multi-variant panel of 8 miRNAs and an algorithm was developed using the Discovery and Optimization Cohort, with an AUC of 0.981 and 0.918 respectively. When validated in the independent Validation Cohort, the panel demonstrated an AUC of 0.915.
Conclusion: We developed and validated a serum miRNA panel that is both sensitive (72.2 - 77.4%) and specific (90.2 - 91.5%) in detecting early stage of breast cancer in both Caucasian and Asian populations.
Citation Format: Lihan Zhou, Ruiyang Zou, Sau Yeen Loke, Mikael Hartman, Patrick C.K Goo, Ann S.G. Lee-Lim, Heng-Phon Too. Identification and validation of a serum microRNA panel for detection of early-stage breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-01-02.
Abstract P5-03-10: The spectrum of BRCA1 and BRCA2 mutations and clinicopathologic characteristics of young-onset breast cancer in BRCA-carriers and non-carriers
Authors: Chen Lili , Fu Fangmeng , Lv Jinxing , Wang Chuan 
Published: March 2020

Abstract
Background: For now, Seldom studies have reported that relationship between BRCA1/2 mutation and their clinical characteristics in young-onset breast cancers. This study is the first article which characterizes the risk factor profiles in Chinese patients selected by the age of onset (&lt;40 years old).Patient and method:A total of 1371 consecutive unselected Chinese young-onset breast cancer patients were collected form Fujian Union hospital, China, screened for germline BRCA1/2 mutation. The full-exome sequencing in the next generation sequencing technology was performed in all patients to examine the BRCA1/2 mutation.Result: In our study, 25 (1.8%) and 61 (4.4%) patients were identified with BRCA1 and BRCA2 mutation among the unselected early-onset breast cancer patients, respectively. BRCA1 mutations were associated with pregnancies (p=0.026), BRCA1-carriers had a higher likelihood of HR positive(p&lt;0.001), or HER-2 negative(p&lt;0.001), or high grade(p=0.002) than non-carriers. Among BRCA2 mutations, the age of onset was younger than non-carriers(P=0.017), BRCA2-carriers were more likely to have lymph node metastasis(P=0.004). with HR positive or HER-2 negative were likely to detected positive for BRCA2(p&lt;0.001).
Citation Format: Lili Chen, Fangmeng Fu, Jinxing Lv, Chuan Wang. The spectrum of BRCA1 and BRCA2 mutations and clinicopathologic characteristics of young-onset breast cancer in BRCA-carriers and non-carriers [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-03-10.
Abstract P5-05-12: Small molecule targeting regulated cell death pathways in treating triple negative breast cancer
Authors: Yenugonda Venkata Mahidhar , Waters Ariana , Yadavalli Sivaramakrishna , Marzese Diego , Senugupta Surojeet , Nurmammadov Elmar , Quan Yueqin , Nomura Natsuko , Allnutt Annamarie , Kesari Santosh 
Published: March 2020

Abstract
The absence of hormone and Her2 receptor expression in triple negative breast cancer (TNBC) precludes the use of targeted therapy available for other breast cancer subtypes, and cytotoxic chemotherapy such as paclitaxel and doxorubicin remains the mainstay of treatment for TNBC. However, patients with TNBC have higher relapse rates, with residual disease after chemotherapy and shorter overall survival, leaving space for further improvement beyond these cytotoxic chemotherapies. We have identified a new chemical entity, VMY- BC-1, that potently blocks growth in TNBC cell lines compared to other breast cancer subgroups or normal-like breast epithelial cells. Our molecule reduces invasion and induces apoptosis in TNBC cell lines. VMY-BC-1 is orally bioavailable and has promising pharmacological properties, and has demonstrated TNBC growth inhibition in vivo. Quantitative proteomics with tandem mass tag (TMT) and Ingenuity Pathway Analysis (IPA) identified significantly altered pathways upon treatment with VMY-BC-1 in the human TNBC cell line, MDA-MB-231. These include activation of the apoptosis, autophagy, and DNA damage pathways, and inhibition of the mTOR1, PI3K, and AKT pathways (Z score = 0.156, p value =1.97E-10). Thermal proteome profiling (TPP) analysis identified proteins interacting with VMY-BC-1 that relate to activated autophagy and DNA damage pathways, such as UNC-51 like kinase 1 (ULK1) and ataxia-telangiectasia mutated (ATM). Importantly, in line with our in vitro observations, in addition to a significantly lower expression of ULK1 on TNBC (T-test; p value = 2.127E-10), we observed that patients with tumors with high ULK1 expression have a larger relapse-free survival (n=3,951; HR=0.77 [0.69-0.86]; log rank; p=5.1E-06). Moreover, our small molecules activated autophagy mediated signaling pathways through ULK1 phosphorylation. These data suggest that autophagy and DNA damage pathways could be therapeutically targeted in TNBC.
Citation Format: Venkata Mahidhar Yenugonda, Ariana Waters, Sivaramakrishna Yadavalli, Diego Marzese, Surojeet Senugupta, Elmar Nurmammadov, Yueqin Quan, Natsuko Nomura, Annamarie Allnutt, Santosh Kesari. Small molecule targeting regulated cell death pathways in treating triple negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-05-12.
Abstract P5-06-07: Desloratadine and loratadine increase breast cancer survival
Authors: Olsson Håkan Lars , Fritz Ildiko , Wagner Philippe 
Published: March 2020

Abstract
Background: As tumors maintain an inflammatory microenvironment, anti-inflammatory medication can be used in cancer therapy. While H2-antihistamines have already shown effects as adjuvant anti-cancer drugs, H1-antihistamines have not been widely studied in this role, though they are among the most ubiquitously used medications globally, and have become increasingly sophisticated, affordable, and safe. Here, we aim to determine the effects of H1-antihistamines on breast cancer mortality.
Methods: We investigated the effects of six H1-antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) on breast cancer-specific and overall mortality in a nation-wide register-based study of all 61,627 Swedish women with newly diagnosed breast cancer July 1st 2005 - December 31st 2013. 14,711 women used H1-antihistamines. Both peri- and post-diagnostic antihistamine use was analyzed, using Cox regression models, and use in patient subgroups based on age or estrogen receptor status.
Results: We found a consistently beneficial effect of desloratadine use (HR = 0·67; 95% CI 0·55-0·81, P &lt; 0·001) on survival, as well as of loratadine use (HR = 0·80; 95% CI 0·67-0·95, P = 0·012), regardless of age or estrogen receptor status, or whether breast cancer-specific or overall survival was analyzed, and a consistently negative effect on survival of clemastine use (HR = 1·45; 95% CI 1·27-1·67, P &lt;0·001).
Conclusions: We suggest immediate trials of desloratadine and loratadine as adjuvant treatment of breast cancer. Especially promising is the results for ER-breast cancer. Further studies on the effects of ebastine and possibly fexofenadine may be merited, as well as further studies of H1-antihistamines, particularly desloratadine, as treatment options for other malignancies.
Breast cancer survival adjusted for prognostic factorsTypeHRLow CIHighCIUp-valueCetirizin1.160.981.350.07clemasine1.341.131.590.0006desloratadine0.680.550.860.001ebastin0.490.270.860.01fexofenadin1.060.571.970.85loratadine0.780.620.960.02
Citation Format: Håkan Lars Olsson, Ildiko Fritz, Philippe Wagner. Desloratadine and loratadine increase breast cancer survival [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-06-07.
Abstract P5-07-12: Prediction and clinical utility of a contralateral breast cancer risk model
Authors: Giardiello Daniele , Steyerberg Ewout W , Hauptmann Michael , Adank Muriel A , Jager Agnes , Oldenburg Hester OA , Hooning Maartje J , Schmidt Marjanka K ,   Breast Cancer Association Consortium
Published: March 2020

Abstract
Background: Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model, and evaluate its applicability for clinical decision-making.
Methods: We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4,682 CBC events and a median follow-up of 8.8 years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics, and BRCA1/2 germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without BRCA1/2 mutation status (PredictCBC-1B). Prediction performance was evaluated using calibration and discrimination, calculated by a time-dependent Area-Under-the-Curve (AUC) at 5 and 10 years after diagnosis of primary breast cancer, and an internal-external cross-validation procedure. Decision curve analysis was performed to evaluate the net benefit of the model to quantify clinical utility.
Results: In the multivariable model, BRCA1/2 germline mutation status, family history and systemic adjuvant treatment showed the strongest associations with CBC risk. The AUC of PredictCBC-1A was 0.63 (95% prediction interval (PI) at 5 years: 0.52–0.74; at 10 years: 0.53–0.72). Calibration in-the-large was -0.13 (95%PI: -1.62–1.37) and the calibration slope was 0.90 (95%PI: 0.73–1.08). The AUC of Predict-1B at 10 years was 0.59 (95% PI: 0.52–0.66); calibration was slightly lower. Decision curve analysis for preventive contralateral mastectomy showed potential clinical utility of PredictCBC-1A between thresholds of 4-10% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers.
Conclusions: We developed a reasonably calibrated model to predict the risk of CBC in women of European-descent, however, prediction accuracy was moderate. Our model shows potential for improved risk counseling, but decision regarding contralateral preventive mastectomy, especially in the general breast cancer population, remains challenging.
Citation Format: Daniele Giardiello, Ewout W Steyerberg, Michael Hauptmann, Muriel A Adank, Agnes Jager, Hester OA Oldenburg, Maartje J Hooning, Marjanka K Schmidt, Breast Cancer Association Consortium. Prediction and clinical utility of a contralateral breast cancer risk model [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-07-12.
Abstract P5-08-23: Personalized, prevention decision aid developed for breast cancer risk-reducing discussions and interventions in the WISDOM study
Authors: Keane Holly , Huilgol Yash , Shibley W. Patrick , Shieh Yiwey , Goodman Deborah , Tice Jeff , Belkora Jeff , Sepucha Karen , Ozzane Elissa , Fiscalini Allison , Esserman Laura 
Published: March 2020

Abstract
Problem statement: Breast cancer risk reduction has been validated by Level I evidence generated in large-scale clinical trials, however uptake of chemoprevention among women at high risk remains very low.
Methods: A patient-facing shared decision-making aid was designed to inform women enrolled in the PCORI-funded WISDOM Study of their individualized breast cancer risk and ways to reduce their risk. It built upon a breast health decision tool used for the prior ten years. The tool displays the key factors that are used to calculate a participant’s risk (Breast Cancer Surveillance Consortium [BCSC] and Polygenic Risk Score). The aid also estimates the anticipated change in a participant’s risk due to particular risk-reduction interventions (medication, lifestyle). After Institutional Review Board approval, we used a mixed-methods analysis to evaluate the decision aid. Expert opinion was sought from decision scientists, low literacy experts, breast health specialists, epidemiologists, and breast cancer specialists, in order to generate a tool with suitable language and adequate communication of content. We piloted the decision-making aid with 15 elevated risk WISDOM Study participants without a common mutation associated with breast cancer.
Results: To date, the pilot has enrolled 10 elevated-risk participants with an average age of 63. Six have completed the quantitative survey. 3 (50%) indicated that they would consider chemoprevention. 6 (100%) indicated that they would consider lifestyle changes, such as exercise or reducing their body mass index (BMI). 3 (50%) indicated the aid has been “extremely helpful” and 6 (100%) indicated that they had a better understanding of their breast cancer risk. Participants also indicated the benefit of visuals and greater engagement with high-risk counselors when using the aid. The full pilot data plus the ongoing experience will be presented.
Conclusion: The WISDOM Study shared decision-making aid represents a novel, participant-centered approach to integrate breast cancer prevention and personal breast cancer risk. This decision aid will be used in the WISDOM Study to evaluate whether risk-based screening will improve uptake of chemoprevention in the WISDOM Study population.
Citation Format: Holly Keane, Yash Huilgol, W. Patrick Shibley, Yiwey Shieh, Deborah Goodman, Jeff Tice, Jeff Belkora, Karen Sepucha, Elissa Ozzane, Allison Fiscalini, Laura Esserman. Personalized, prevention decision aid developed for breast cancer risk-reducing discussions and interventions in the WISDOM study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-08-23.
Abstract P5-11-20: Efficacy observation of 306 patients with fulvestrant 500mg treatment in hormone-receptor positive HER2 negative metastasis breast cancer, a real world study
Authors: Lei Wen , Li Huiping , Song Guohong , Zhang Ruyan , Ran Ran , Yan Ying 
Published: March 2020

Abstract
Background: Fulvestrant 500mg has been proved better efficacy in breast cancer with hormone receptor positive (HR+),and then become an optional strategy for primary or second line treatment of HR+ positive metastasis breast cancer (MBC).
Methods: In this real world study, we retrospectively analyzed the patients with HR+ HER 2 negative MBC who received fulvestrant 500mg treatment at Beijing cancer hospital during January 2015 to December 2018. Clinical benefit rate (CBR), progression free survival (PFS), overall survival (OS) and adverse events were investigated.
Results: There were 306 patients enrolled, median age was 48.7(range 20-75) years, median line of fulvestrant was 2.11(range 1-6), 68.3%(209/306) patients were involved with visceral metastasis. The CBR was 68.6%, median PFS was 8.41m (95%CI: 7.079m-9.743m, range 0.89m-80.16m). Among the patients received fulvestrant at the first line, the PFS was 10.55m(95%CI:6.46m-14.64m, range 0.92m-34.3m). The median OS hasn’t been obtained. In subgroup analysis, the patients without liver metastasis(12.49m vs. 4.60m, p&lt;0.001), small tumor burden(metastasis number 1-2 vs. 3-4 vs. &gt;4, 12.65m vs. 7.72m vs. 3.98m respectively, p&lt;0.001) and experience no or less line of chemotherapy(none vs. 1-2 lines vs. &gt;2 lines, 14.06m vs. 7.79m vs. 3.52m respectively, p&lt;0.001) for metastatic disease were obtained more benefit from fulvestrant treatment. For patients with visceral metastasis, the patients absence of liver metastasis was corelated with longer PFS 9.27m than 4.60m(p&lt;0.001). There were 20(6.54%) adverse events occurred in 306 patients, 95%(19/20) were grade 1-2. The most common adverse event was oral ulcer, and serious adverse events were observed in 1 patients (0.33%) with pulmonary embolism.
Conclusions: Fulvestrant was an effective and safe regimen in endocrine therapy for hormone receptor positive HER2 negative MBC. The patients who were in first line treatment, absence of liver metastasis and small tumor burden might be more benefit from fulvestrant.
Corresponding authors: Huiping Li, huipingli2012@hotmail.com; Guohong Song, songguohong918@hotmail.com, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, 52 Fucheng Rd, Beijing 100142, China
Citation Format: Wen Lei, Huiping Li, Guohong Song, Ruyan Zhang, Ran Ran, Ying Yan. Efficacy observation of 306 patients with fulvestrant 500mg treatment in hormone-receptor positive HER2 negative metastasis breast cancer, a real world study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-11-20.